PolyPid announces publication of preclinical data on D-PLEX100

PolyPid announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals. These preclinical data were published in the peer-reviewed journal, International Journal of Toxicology, in a paper titled, “Preclinical In-Vivo Safety and Toxicokinetics of D-PLEX100 in an Abdominal Surgery Incision Model in Juvenile Miniature Swine.” The safety and toxicokinetics of D-PLEX100 were tested following its administration via an abdominal incision to juvenile swine. The animals were evaluated for a period of nine months and no treatment-related adverse events were observed during this period. PolyPid’s ongoing Phase 3 SHIELD II trial of D-PLEX100 for the prevention of surgical site infections is currently recruiting patients undergoing open abdominal colorectal surgery with large incisions. Top-line results are expected in mid-2024.